WEDNESDAY, 10th APRIL 2019 COMMENCING 10:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Limited Submission (PAS)
   Blinatumomab (Blincyto®) as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation

6. Appraisal 2: Limited Submission (PAS)
   Mepolizumab (Nucala®) as add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older

The meeting will now open to the public for the committee decisions

7. Chairman's report (verbal update)

Date of next meeting – Wednesday, 15th May 2019 in Cardiff